ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is efficiently used in the clinical treatment of BCR-ABL-driven CML, but possible BCRP-mediated imatinib resistance would naturally affect the efficacy of the treatment.